Roadmap to Pyruvate Kinase M2 Modulation-A Computational Chronicle

被引:2
|
作者
Kapoor, Saumya [1 ]
Chatterjee, Deep Rohan [1 ]
Chowdhury, Moumita Ghosh [1 ]
Das, Rudradip [1 ]
Shard, Amit [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res, Dept Med Chem, Opposite Air Force Stn Palaj, Ahmadabad 382355, Gujarat, India
关键词
CADD; cancer; in silico; modulators; pyruvate kinase M2; QSAR; anti-cancer therapy; MOLECULAR-DYNAMICS; ALLOSTERIC REGULATION; LIGAND DOCKING; CDNA CLONING; INHIBITORS; PROTEIN; DESIGN; PKM2; ACTIVATION; DISCOVERY;
D O I
10.2174/1389450124666230330103126
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pyruvate kinase M2 (PKM2) has surfaced as a potential target for anti-cancer therapy. PKM2 is known to be overexpressed in the tumor cells and is a critical metabolic conduit in supplying the augmented bioenergetic demands of the recalcitrant cancer cells. The presence of PKM2 in structurally diverse tetrameric as well as dimeric forms has opened new avenues to design novel modulators. It is also a truism to state that drug discovery has advanced significantly from various computational techniques like molecular docking, virtual screening, molecular dynamics, and pharmacophore mapping. The present review focuses on the role of computational tools in exploring novel modulators of PKM2. The structural features of various isoforms of PKM2 have been discussed along with reported modulators. An extensive analysis of the structure-based and ligand-based in silico methods aimed at PKM2 modulation has been conducted with an in-depth review of the literature. The role of advanced tools like QSAR and quantum mechanics has been established with a brief discussion of future perspectives.
引用
收藏
页码:464 / 483
页数:20
相关论文
共 50 条
  • [21] Pyruvate kinase M2: A simple molecule with complex functions
    Alquraishi, Mohammed
    Puckett, Dexter L.
    Alani, Dina S.
    Humidat, Amal S.
    Frankel, Victoria D.
    Donohoe, Dallas R.
    Whelan, Jay
    Bettaieb, Ahmed
    FREE RADICAL BIOLOGY AND MEDICINE, 2019, 143 : 176 - 192
  • [22] Pyruvate kinase M2 is a phosphotyrosine-binding protein
    Christofk, Heather R.
    Vander Heiden, Matthew G.
    Wu, Ning
    Asara, John M.
    Cantley, Lewis C.
    NATURE, 2008, 452 (7184) : 181 - U27
  • [23] Pyruvate kinase type M2: a crossroad in the tumor metabolome
    Mazurek, S
    Grimm, H
    Boschek, CB
    Vaupel, P
    Eigenbrodt, E
    BRITISH JOURNAL OF NUTRITION, 2002, 87 : S23 - S29
  • [24] Pyruvate Kinase M2: A Potential Target for Regulating inflammation
    Alves-Filho, Jose C.
    Palsson-McDermott, Eva M.
    FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [25] Targeting pyruvate kinase M2 for the treatment of kidney disease
    Chen, Dan-Qian
    Han, Jin
    Liu, Hui
    Feng, Kai
    Li, Ping
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [26] PYRUVATE KINASE M2 ACTIVATORS INHIBIT TUMOR GROWTH
    不详
    CANCER DISCOVERY, 2012, 2 (10) : 866 - 866
  • [27] Identification of small molecule inhibitors of pyruvate kinase M2
    Vander Heiden, Matthew G.
    Christofk, Heather R.
    Schuman, Eli
    Subtelny, Alexander O.
    Sharfi, Hadar
    Harlow, Edward E.
    Xian, Jun
    Cantley, Lewis C.
    BIOCHEMICAL PHARMACOLOGY, 2010, 79 (08) : 1118 - 1124
  • [28] Role of pyruvate kinase M2 in regulating sepsis (Review)
    Hu, Yifei
    Tang, Jing
    Xu, Qiao
    Fang, Zenghui
    Li, Rongqing
    Yang, Mengxuan
    Zhao, Jie
    Chen, Xin
    MOLECULAR MEDICINE REPORTS, 2024, 30 (04)
  • [29] STUDIES ON PHOSPHORYLATION AND INACTIVATION OF PYRUVATE-KINASE M2
    EIGENBRODT, E
    SCHERING, B
    BRUNN, H
    SCHONER, W
    HOPPE-SEYLERS ZEITSCHRIFT FUR PHYSIOLOGISCHE CHEMIE, 1978, 359 (03): : 260 - 260
  • [30] Isoform Switch of Pyruvate Kinase M1 Indeed Occurs but Not to Pyruvate Kinase M2 in Human Tumorigenesis
    Zhan, Cheng
    Yan, Li
    Wang, Lin
    Ma, Jun
    Jiang, Wei
    Zhang, Yongxing
    Shi, Yu
    Wang, Qun
    PLOS ONE, 2015, 10 (03):